Q2 Earnings Forecast for Nuvalent Issued By Leerink Partnrs

Nuvalent, Inc. (NASDAQ:NUVL) – Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Nuvalent in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($1.17) per share for the quarter. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent’s Q3 2025 earnings at ($1.18) EPS and Q4 2025 earnings at ($1.10) EPS.

Other analysts have also issued reports about the stock. Wedbush reissued an “outperform” rating and set a $115.00 target price on shares of Nuvalent in a research note on Monday, January 13th. BMO Capital Markets upped their price objective on shares of Nuvalent from $132.00 to $134.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. UBS Group initiated coverage on shares of Nuvalent in a research note on Thursday, October 24th. They issued a “neutral” rating and a $100.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Nuvalent in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $112.36.

Nuvalent Trading Down 2.5 %

NUVL stock opened at $86.70 on Friday. Nuvalent has a twelve month low of $61.79 and a twelve month high of $113.51. The firm’s fifty day simple moving average is $83.93 and its two-hundred day simple moving average is $87.87.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.35). During the same quarter last year, the company posted ($0.59) EPS.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, CEO James Richard Porter sold 27,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $86.61, for a total value of $2,338,470.00. Following the completion of the sale, the chief executive officer now directly owns 188,113 shares of the company’s stock, valued at $16,292,466.93. This trade represents a 12.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Henry E. Pelish sold 2,483 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $79.68, for a total value of $197,845.44. Following the sale, the insider now directly owns 59,981 shares of the company’s stock, valued at $4,779,286.08. The trade was a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,800 shares of company stock worth $6,812,164. Corporate insiders own 12.52% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

Several institutional investors have recently bought and sold shares of the company. FMR LLC grew its position in shares of Nuvalent by 8.9% during the third quarter. FMR LLC now owns 9,654,352 shares of the company’s stock worth $987,640,000 after buying an additional 786,257 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Nuvalent by 65.5% in the third quarter. Wellington Management Group LLP now owns 1,011,837 shares of the company’s stock valued at $103,511,000 after acquiring an additional 400,402 shares during the period. Geode Capital Management LLC raised its stake in shares of Nuvalent by 9.4% during the third quarter. Geode Capital Management LLC now owns 855,610 shares of the company’s stock worth $87,546,000 after purchasing an additional 73,429 shares during the last quarter. Fred Alger Management LLC raised its stake in shares of Nuvalent by 8.6% during the third quarter. Fred Alger Management LLC now owns 627,742 shares of the company’s stock worth $64,218,000 after purchasing an additional 49,612 shares during the last quarter. Finally, Candriam S.C.A. raised its stake in shares of Nuvalent by 15.6% during the fourth quarter. Candriam S.C.A. now owns 368,095 shares of the company’s stock worth $28,814,000 after purchasing an additional 49,728 shares during the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.